Esprinet S.p.A. (BIT:PRT) Analysts Are Pretty Bullish On The Stock After Recent Results
Shareholders of Esprinet S.p.A. (BIT:PRT) will be pleased this week, given that the stock price is up 11% to €8.54 following its latest half-year results. Results were roughly in line with estimates, with revenues of €2.1b and statutory earnings per share of €0.41. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.
Following last week's earnings report, Esprinet's four analysts are forecasting 2026 revenues to be €4.53b, approximately in line with the last 12 months. Statutory earnings per share are predicted to soar 33% to €0.58. Yet prior to the latest earnings, the analysts had been anticipated revenues of €4.50b and earnings per share (EPS) of €0.54 in 2026. The analysts seems to have become more bullish on the business, judging by their new earnings per share estimates.
See our latest analysis for Esprinet
The consensus price target rose 12% to €8.80, suggesting that higher earnings estimates flow through to the stock's valuation as well. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. There are some variant perceptions on Esprinet, with the most bullish analyst valuing it at €9.00 and the most bearish at €8.50 per share. Even so, with a relatively close grouping of estimates, it looks like the analysts are quite confident in their valuations, suggesting Esprinet is an easy business to forecast or the the analysts are all using similar assumptions.
Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. One thing stands out from these estimates, which is that Esprinet is forecast to grow faster in the future than it has in the past, with revenues expected to display 3.7% annualised growth until the end of 2026. If achieved, this would be a much better result than the 2.8% annual decline over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenue grow 5.7% per year. So although Esprinet's revenue growth is expected to improve, it is still expected to grow slower than the industry.
The Bottom Line
The biggest takeaway for us is the consensus earnings per share upgrade, which suggests a clear improvement in sentiment around Esprinet's earnings potential next year. Fortunately, the analysts also reconfirmed their revenue estimates, suggesting that it's tracking in line with expectations. Although our data does suggest that Esprinet's revenue is expected to perform worse than the wider industry. We note an upgrade to the price target, suggesting that the analysts believes the intrinsic value of the business is likely to improve over time.
With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have forecasts for Esprinet going out to 2028, and you can see them free on our platform here.
It is also worth noting that we have found 2 warning signs for Esprinet (1 is a bit unpleasant!) that you need to take into consideration.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.